Related Experiment Video
Updated: Jul 12, 2026
07:40
Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
Published on: January 12, 2022
High-dose infliximab prophylaxis in endotoxin-induced uveitis
Manuel Diaz-Llopis1, Salvador García-Delpech, David Salom
1Department of Ophthalmology, Uveitis Unit, Hospital General Universitario, Valencia, Spain. manuel.diaz@uv.es
Summary
High-dose infliximab effectively prevents endotoxin-induced uveitis (EIU) in rabbits. This treatment significantly reduced inflammation, inflammatory cells, and protein levels in the eye.
Area of Science:
- Ophthalmology
- Immunology
- Pharmacology
Background:
- Endotoxin-induced uveitis (EIU) is a common experimental model for intraocular inflammation.
- Tumor necrosis factor-alpha (TNF-alpha) plays a key role in the pathogenesis of EIU.
Purpose of the Study:
- To evaluate the preventive efficacy of high-dose infliximab in a rabbit model of EIU.
- To assess the impact of infliximab on inflammatory markers in EIU.
Main Methods:
- An experimental study involving 64 rabbits with induced uveitis.
- Intravenous infliximab (20 mg/kg) administered 24 hours prior to endotoxin injection.
- Microscopic examination of aqueous humor for cells, TNF-alpha, and protein levels.
Main Results:
- Infliximab treatment significantly reduced inflammatory cell infiltration in the iris, ciliary body, and anterior chamber.
- A significant decrease in aqueous humor TNF-alpha levels and protein exudate was observed.
- All evaluated inflammatory parameters showed significant improvement (P = 0.01).
Conclusions:
- High-dose infliximab (20 mg/kg) demonstrates significant prophylactic effects against EIU in rabbits.
- Infliximab is an effective therapeutic agent for preventing endotoxin-induced ocular inflammation.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...